Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism.
Lower doses of clot-busting medication worked as safely as standard doses for dangerous blood clots, potentially reducing treatment side effects.
This retrospective comparative cohort study examined Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism. In-hospital mortality did not differ significantly between groups (48% in the low-dose group vs 45% in the standard-dose group; P = .81).
What the study was
- Study design
- Retrospective comparative cohort study
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- American journal of critical care : an official publication, American Association of Critical-Care Nurses
Why it surfaced
Abstract-backed retrospective comparative cohort study relevant to a high-signal out-of-watchlist clinical question; scored conservatively because full text was not assessed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.